Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer

Endocrine therapy is a recognised option in the treatment of chemo-resistant ovarian cancer. We conducted a nonrandomised phase II evaluation of combination endocrine therapy with tamoxifen and goserelin in patients with advanced ovarian cancer that had recurred following chemotherapy. In total, 26...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasan, J, Ton, N, Mullamitha, S, Clamp, A, McNeilly, A, Marshall, E, Jayson, G C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361624/
https://www.ncbi.nlm.nih.gov/pubmed/16222310
http://dx.doi.org/10.1038/sj.bjc.6602752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361624/
https://www.ncbi.nlm.nih.gov/pubmed/16222310
http://dx.doi.org/10.1038/sj.bjc.6602752

Ejemplares similares